Last reviewed · How we verify
IDX-1197
At a glance
| Generic name | IDX-1197 |
|---|---|
| Sponsor | Idience Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer (PHASE1, PHASE2)
- Basket Trial of IDX-1197, a PARP Inhibitor, in Patients with HRR Mutated Solid Tumors (VASTUS) (PHASE1, PHASE2)
- Food Effect Study of IDX-1197 in Healthy Subjects (PHASE1)
- Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IDX-1197 CI brief — competitive landscape report
- IDX-1197 updates RSS · CI watch RSS
- Idience Co., Ltd. portfolio CI